
    
      The primary objective of this study is to demonstrate non-inferiority of efficacy determined
      by the proportion of subjects who develop hepatotoxicity when treated with a new formulation
      of Acetadote and the proposed new dosing regimen compared to the rate of hepatotoxicity with
      the current formulation of Acetadote and the current dosing regimen.
    
  